Study analysis · Journal of Atherosclerosis and Thrombosis · 2026
Drop your bad cholesterol by half after a stent and cut your relative risk of heart events by 50% — but the absolute benefit remains a mystery.
In people who had a stent procedure, getting bad cholesterol down by 50% or more was linked to half the relative risk of heart problems or repeat procedures compared to those who lowered it less.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at patients who had a heart procedure and checked if lowering their cholesterol a lot was linked to fewer heart problems later. Because it just observed people without randomly assigning treatments, it can only show that lower cholesterol and fewer heart problems go together, but it can't prove that lowering cholesterol directly causes fewer problems.
What’s the bottom line?
Researchers looked back at 826 people who had a stent procedure (PCI). They checked how much their LDL cholesterol dropped from before treatment to follow-up, and whether that related to later heart problems or repeat procedures.
How strong is this study?
The study was done well for an observation study: it included many patients, used advanced statistics to account for other factors, and did extra checks to make sure the results were reliable. However, since it wasn't a randomized experiment, we can't be sure that other things aren't causing the difference, so we should be cautious about trusting the results as proof of cause and effect.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control group+15/15
- Sample size (n=826)+19.7/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Observational cohort design without randomization; confounding by indication and other unmeasured factors cannot be excluded; findings are associative only.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding statement was present in the provided text, so potential conflicts cannot be assessed.
The provided study text does not include a conflict of interest, funding, or author affiliation section. It appears to be an excerpt ending mid-sentence. No industry ties or funding sources can be identified from the available text.
Key takeaways
- 01
Greater relative LDL-C reduction was linked to lower relative hazard of heart events.
- 02
Compared with less than 30% reduction, 30–49% reduction had a 37% lower relative hazard (HR 0.63), and ≥50% reduction had a 50% lower relative hazard (HR 0.50).
- 03
Achieving LDL-C below 55 mg/dL had a 60% lower relative hazard (HR 0.40).
- 04
Achieving both ≥50% reduction and LDL-C below 55 mg/dL had a 73% lower relative hazard (HR 0.27).
- 05
These are relative hazards; absolute event rates by group were not reported.
- 06
The study did not report absolute event rates for each LDL-C reduction group, so we cannot say exactly how many fewer people had events.
- 07
Overall, 400 of 826 patients (~48%) had a first composite event over median 12 months, but that is across all groups and not a group-specific absolute risk.
- 08
The relative hazard reductions are large, but without absolute numbers the real-world benefit per person is unclear.
Surprising findings
- Achieving only one of the two targets (either ≥50% reduction or LDL-C <55 mg/dL) was not significantly associated with lower risk (HR 0.87, 95% CI 0.58–1.31).Many might assume that hitting either target would confer some benefit, but this study suggests both are needed for a clear association with lower risk.
- The association between relative LDL-C reduction and outcomes was modified by achieved LDL-C level, with the lowest risk when large reductions (~60–70%) occurred together with low on-treatment LDL-C.It implies that the prognostic impact of LDL lowering cannot be captured by either metric alone; the combination matters. This challenges the idea that you can focus solely on one target.
Practical takeaways
If you have had a stent, work with your doctor to aim for both a ≥50% reduction in LDL cholesterol from your baseline and an LDL level below 55 mg/dL. This combination was linked to the lowest relative risk of future heart events.
This is an observational study, so it doesn't prove that hitting these targets causes better outcomes. Also, absolute risk reduction was not reported, so we don't know exactly how many events would be prevented.
medium confidenceDon't just focus on the final LDL number—track how much it has dropped from your starting point. A large relative reduction may be just as important as the absolute level.
The study was single-center, retrospective, and had a median follow-up of only 12 months. Results may not apply to everyone, especially those with very low baseline LDL.
medium confidenceWhy this study matters
The 50% threshold: a sweet spot for LDL reduction?
Patients achieving ≥50% relative LDL-C reduction had a 50% lower relative hazard of MACE+revascularization (HR 0.50, 95% CI 0.32–0.80) compared to those with <30% reduction. Even a 30–49% reduction was linked to a 37% lower relative hazard (HR 0.63). The association was nonlinear, with risk dropping steeply after ~30% reduction.
It suggests that how much you lower cholesterol matters, not just the final number. But these are relative risks; absolute risk reduction was not reported, so we don't know how many actual events were prevented.
Hitting both targets: the power of dual goals
Achieving both ≥50% reduction and LDL-C <55 mg/dL was associated with a 73% lower relative hazard (HR 0.27) compared to neither. Interestingly, achieving only one target was not significantly associated with lower risk (HR 0.87).
It's not enough to just get your LDL low or just reduce it a lot—you need both. This supports the dual-target strategy in guidelines, but the observational nature means we can't prove cause and effect.
The lower, the better—but how low can we go?
The spline curve suggested the lowest risk at 60–70% LDL reduction, but only 32 patients achieved ≥60% reduction and 7 achieved ≥70%. The authors caution against interpreting this as an optimal target due to sparse data.
It raises the question: is there a limit to how much LDL reduction is beneficial? Or do we just lack data at the extremes? This is a hot topic with new drugs like PCSK9 inhibitors.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers looked back at 826 people who had a stent procedure (PCI). They checked how much their LDL cholesterol dropped from before treatment to follow-up, and whether that related to later heart problems or repeat procedures.
Research results
Greater relative LDL-C reduction was linked to lower relative hazard of heart events. Compared with less than 30% reduction, 30–49% reduction had a 37% lower relative hazard (HR 0.63), and ≥50% reduction had a 50% lower relative hazard (HR 0.50). Achieving LDL-C below 55 mg/dL had a 60% lower relative hazard (HR 0.40). Achieving both ≥50% reduction and LDL-C below 55 mg/dL had a 73% lower relative hazard (HR 0.27). These are relative hazards; absolute event rates by group were not reported.
What this means - more context
The study did not report absolute event rates for each LDL-C reduction group, so we cannot say exactly how many fewer people had events. Overall, 400 of 826 patients (~48%) had a first composite event over median 12 months, but that is across all groups and not a group-specific absolute risk. The relative hazard reductions are large, but without absolute numbers the real-world benefit per person is unclear.
Evaluate whether relative LDL-C reduction from baseline is associated with cardiovascular outcomes after PCI, and how it jointly relates to achieved LDL-C levels.
Retrospective single-center cohort of 826 patients undergoing PCI (2006–2016). Greater relative LDL-C reduction was associated with progressively lower relative hazard of 3-point MACE plus any revascularization in a nonlinear dose-response. Achieving ≥50% relative reduction and achieving LDL-C <55 mg/dL were each associated with lower relative hazard, and achieving both was associated with the lowest relative hazard. Absolute event rates by exposure group were not reported, and causality cannot be inferred.
Methods Used
Retrospective cohort of consecutive PCI patients at one tertiary center. Relative LDL-C reduction calculated from baseline to follow-up measurement. Primary outcome: 3-point MACE plus any coronary revascularization. Cox proportional hazards with restricted cubic splines, categorical thresholds, and generalized additive models; median follow-up 12.0 months (IQR 7.0–34.0).
Main Finding
Greater relative LDL-C reduction was associated with lower relative hazard of the primary composite outcome (overall P=0.0001; nonlinearity P=0.0007). Compared with <30% reduction, 30–49% reduction had HR 0.63 (37% lower relative hazard; 95% CI 0.46–0.87) and ≥50% reduction had HR 0.50 (50% lower relative hazard; 95% CI 0.32–0.80). Achieved LDL-C <55 mg/dL had HR 0.40 (60% lower relative hazard; 95% CI 0.22–0.74). Achieving both ≥50% reduction and LDL-C <55 mg/dL had HR 0.27 (73% lower relative hazard; 95% CI 0.11–0.66) versus neither. Absolute event rates by exposure category were not reported.
Confidence Level
Moderate-to-low. Observational, retrospective, single-center, limited sample size at extreme LDL-C reductions, single follow-up LDL-C measurement, residual confounding likely; no absolute risk by group reported.
Study Flags
Red Flags
- •Retrospective single-center observational design; residual confounding and no causal inference
- •Absolute event rates by LDL-C reduction category not reported, limiting interpretation of real-world benefit
- •Small number of patients at extreme LDL-C reductions and single follow-up LDL-C measurement; follow-up median only 12 months
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Achieving only one of the two targets (either ≥50% reduction or LDL-C <55 mg/dL) was not significantly associated with lower risk (HR 0.87, 95% CI 0.58–1.31).
Many might assume that hitting either target would confer some benefit, but this study suggests both are needed for a clear association with lower risk.
Practical Takeaways
If you have had a stent, work with your doctor to aim for both a ≥50% reduction in LDL cholesterol from your baseline and an LDL level below 55 mg/dL. This combination was linked to the lowest relative risk of future heart events.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
High probability
on the GRADE evidence scale
This study looked at patients who had a heart procedure and checked if lowering their cholesterol a lot was linked to fewer heart problems later. Because it just observed people without randomly assigning treatments, it can only show that lower cholesterol and fewer heart problems go together, but it can't prove that lowering cholesterol directly causes fewer problems.
Strengths
- Large sample size (826 patients) for a single-center study.
- Use of restricted cubic splines to model non-linear relationships.
- Adjustment for multiple confounders including age, sex, hypertension, diabetes, BMI, eGFR, and SYNTAX score.
Weaknesses
- Observational, retrospective design precludes causal inference.
- Potential for unmeasured confounding (e.g., statin adherence, treatment intensity, familial hypercholesterolemia).
- Single follow-up LDL-C measurement may not capture dynamic changes.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers looked back at 826 people who had a stent procedure (PCI). They checked how much their LDL cholesterol dropped from before treatment to follow-up, and whether that related to later heart problems or repeat procedures.
Research results
Greater relative LDL-C reduction was linked to lower relative hazard of heart events. Compared with less than 30% reduction, 30–49% reduction had a 37% lower relative hazard (HR 0.63), and ≥50% reduction had a 50% lower relative hazard (HR 0.50). Achieving LDL-C below 55 mg/dL had a 60% lower relative hazard (HR 0.40). Achieving both ≥50% reduction and LDL-C below 55 mg/dL had a 73% lower relative hazard (HR 0.27). These are relative hazards; absolute event rates by group were not reported.
What this means - more context
The study did not report absolute event rates for each LDL-C reduction group, so we cannot say exactly how many fewer people had events. Overall, 400 of 826 patients (~48%) had a first composite event over median 12 months, but that is across all groups and not a group-specific absolute risk. The relative hazard reductions are large, but without absolute numbers the real-world benefit per person is unclear.
Evaluate whether relative LDL-C reduction from baseline is associated with cardiovascular outcomes after PCI, and how it jointly relates to achieved LDL-C levels.
Retrospective single-center cohort of 826 patients undergoing PCI (2006–2016). Greater relative LDL-C reduction was associated with progressively lower relative hazard of 3-point MACE plus any revascularization in a nonlinear dose-response. Achieving ≥50% relative reduction and achieving LDL-C <55 mg/dL were each associated with lower relative hazard, and achieving both was associated with the lowest relative hazard. Absolute event rates by exposure group were not reported, and causality cannot be inferred.
Methods Used
Retrospective cohort of consecutive PCI patients at one tertiary center. Relative LDL-C reduction calculated from baseline to follow-up measurement. Primary outcome: 3-point MACE plus any coronary revascularization. Cox proportional hazards with restricted cubic splines, categorical thresholds, and generalized additive models; median follow-up 12.0 months (IQR 7.0–34.0).
Main Finding
Greater relative LDL-C reduction was associated with lower relative hazard of the primary composite outcome (overall P=0.0001; nonlinearity P=0.0007). Compared with <30% reduction, 30–49% reduction had HR 0.63 (37% lower relative hazard; 95% CI 0.46–0.87) and ≥50% reduction had HR 0.50 (50% lower relative hazard; 95% CI 0.32–0.80). Achieved LDL-C <55 mg/dL had HR 0.40 (60% lower relative hazard; 95% CI 0.22–0.74). Achieving both ≥50% reduction and LDL-C <55 mg/dL had HR 0.27 (73% lower relative hazard; 95% CI 0.11–0.66) versus neither. Absolute event rates by exposure category were not reported.
Confidence Level
Moderate-to-low. Observational, retrospective, single-center, limited sample size at extreme LDL-C reductions, single follow-up LDL-C measurement, residual confounding likely; no absolute risk by group reported.
Study Flags
Red Flags
- •Retrospective single-center observational design; residual confounding and no causal inference
- •Absolute event rates by LDL-C reduction category not reported, limiting interpretation of real-world benefit
- •Small number of patients at extreme LDL-C reductions and single follow-up LDL-C measurement; follow-up median only 12 months
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Achieving only one of the two targets (either ≥50% reduction or LDL-C <55 mg/dL) was not significantly associated with lower risk (HR 0.87, 95% CI 0.58–1.31).
Many might assume that hitting either target would confer some benefit, but this study suggests both are needed for a clear association with lower risk.
Practical Takeaways
If you have had a stent, work with your doctor to aim for both a ≥50% reduction in LDL cholesterol from your baseline and an LDL level below 55 mg/dL. This combination was linked to the lowest relative risk of future heart events.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
High probability
on the GRADE evidence scale
This study looked at patients who had a heart procedure and checked if lowering their cholesterol a lot was linked to fewer heart problems later. Because it just observed people without randomly assigning treatments, it can only show that lower cholesterol and fewer heart problems go together, but it can't prove that lowering cholesterol directly causes fewer problems.
Strengths
- Large sample size (826 patients) for a single-center study.
- Use of restricted cubic splines to model non-linear relationships.
- Adjustment for multiple confounders including age, sex, hypertension, diabetes, BMI, eGFR, and SYNTAX score.
Weaknesses
- Observational, retrospective design precludes causal inference.
- Potential for unmeasured confounding (e.g., statin adherence, treatment intensity, familial hypercholesterolemia).
- Single follow-up LDL-C measurement may not capture dynamic changes.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was done well for an observation study: it included many patients, used advanced statistics to account for other factors, and did extra checks to make sure the results were reliable. However, since it wasn't a randomized experiment, we can't be sure that other things aren't causing the difference, so we should be cautious about trusting the results as proof of cause and effect.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control group+15/15
- Sample size (n=826)+19.7/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 572 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Observational cohort design without randomization; confounding by indication and other unmeasured factors cannot be excluded; findings are associative only.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding statement was present in the provided text, so potential conflicts cannot be assessed.
The provided study text does not include a conflict of interest, funding, or author affiliation section. It appears to be an excerpt ending mid-sentence. No industry ties or funding sources can be identified from the available text.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Good evidence
Good evidence supports this claim, with little to contradict it.
Evidence
Authored by
7 researchersIf this is your work, this is how we attribute it on Fit Body Science. Tetsuji Morishita is listed as the lead author.